Last updated on November 2019

A 28 Day Parallel Group Study to Assess the Effects of RDN-929

Brief description of study

Eligibility will be assessed during a screening period of up to 4 weeks. Subjects will take study medication once daily up to and including Day 28. Safety, tolerability and PK will be measured at each visit.

Clinical Study Identifier: NCT03963973

Find a site near you

Start Over

QPS Netherlands B.V.

Leeuwarden, Netherlands
  Connect »

Brain Research Center

Amsterdam, Netherlands
  Connect »